Webcast - Oncopeptides withdraw Pepaxto® in US, scale down organization and focus on R&D
October 22, 2021, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Investors, financial analysts and media were invited to participate in a webcast with a Q&A session at 16:30 (CET). The event was hosted by CEO, Marty J Duvall, CMO, Klaas Bakker and CSO Jakob Lindberg.